Estella Aparecida de Laia

Estella Aparecida de Laia

Auto-generated profile, based on publicly available information

Estella Aparecida de Laia

Department of Medicine, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
GRGiulia Almiron da RSoares
Giulia Almiron da RSoares
AGAmanda Godoi
Amanda Godoi
PMPatricia Marcolin
Patricia Marcolin
GPGabriel Piredda
Gabriel Piredda
ELEstella Laia
Estella Laia
ARAirton Zogaib Rodrigues
Airton Zogaib Rodrigues

20 March 2025 in Clinical Breast Cancer
Verified
Journal Article
Closed access
Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
VSVitor Kendi Tsuchiya Sano
Vitor Kendi Tsuchiya Sano
CPCaroline R M Pereira
Caroline R M Pereira
ELEstella Aparecida de Laia
Estella Aparecida de Laia
CSCarlos Stecca
Carlos Stecca
PTPaolo Tarantino
Paolo Tarantino

25 January 2025 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
ELEstella Aparecida de Laia
Estella Aparecida de Laia
VSVitor Kendi Tsuchiya Sano
Vitor Kendi Tsuchiya Sano
ASAline Gabriele Etur dos Santos
Aline Gabriele Etur dos Santos
CPCaroline R M Pereira
Caroline R M Pereira
Rommel Mario BurbanoRommel Mario Burbano
Rommel Mario Burbano
Colorectal cancer is the second leading cause of cancer-related deaths worldwide. The impact of proton pump inhibitors (PPIs) on patients taking capecitabine, an oral fluoropyrimidine, remains uncertain, despite their use by 20 to 55% of cancer patients. We investigated how PPIs affect the effectiveness of capecitabine in treating colorectal cancer. We searched PubMed, Embase, and Web of Science databases for studies that investigated the use of PPI with capecitabine versus capecitabine alone. We used random-effects models for all endpoints. Heterogeneity was assessed using I2 statistics. We included 676 patients receiving capecitabine monotherapy. The overall progression/disease-free survival favored the PPI non-users (HR 2.1372; 95% CI 1.4591-3.1306; p < 0.001). Our results show that there seems to be no difference between users of PPIs and capecitabine in the colorectal cancer patients (HR 1.5922; 95% CI 0.9718-2.6086; p = 0.065). However, after sensitivity-adjusted analysis, PPI use was negatively associated with PPI use (HR 2.14; 95% CI 1.14-4.01; p < 0.001). Patients with colorectal cancer undergoing oral chemotherapy, specifically capecitabine, should be monitored for the use of PPIs. Therefore, the use of PPIs should be discouraged in clinical practice in these cases. www.crd.york.ac.uk/prospero identifier is CRD42024498240.

1 January 2024
Verified
Book Chapter
Closed access
MPMariana de Paula Pires
Mariana de Paula Pires
PGPedro Barbosa Gomes
Pedro Barbosa Gomes
BCBeatriz Mello da Silveira Campos
Beatriz Mello da Silveira Campos
TFThamiriz Guilarducci Fernandes
Thamiriz Guilarducci Fernandes
ELEstella Aparecida de Laia
Estella Aparecida de Laia
PFPriscila Pollo Flores
Priscila Pollo Flores
Publique sua obra como capítulo de Livro na Editora SCISAÚDE. DOI. Ficha Catalográfica. ISBN. Fique por dentro de nosso congressos @scisaude